Tecan Group (TECN) Stock Overview
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for TECN from our risk checks.
TECN Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Tecan Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 151.70 |
| 52 Week High | CHF 177.50 |
| 52 Week Low | CHF 110.60 |
| Beta | 1.06 |
| 1 Month Change | 12.20% |
| 3 Month Change | 24.86% |
| 1 Year Change | -11.55% |
| 3 Year Change | -57.70% |
| 5 Year Change | -65.52% |
| Change since IPO | 223.45% |
Recent News & Updates
TECN: Reduced P/E Expectations Will Limit Perceived Upside Potential
Analysts have trimmed their price targets on Tecan Group by CHF 1 to CHF 10 in recent updates. This reflects revised assumptions around discount rates, profit margins and future P/E expectations.TECN: Updated Discount Assumptions Will Shape Perceived Upside Potential
Tecan Group's analyst price target has been reduced by CHF 1 to CHF 136, as analysts factor in updated discount rate and valuation assumptions, along with modest adjustments to revenue growth, profit margin and future P/E inputs. Analyst Commentary Recent research points to a more cautious tone around Tecan Group, with reduced price targets reflecting reassessed assumptions on growth, profitability and valuation multiples.TECN: AI Lab Collaboration And Execution Discipline Will Support Future Earnings
The analyst price target for Tecan Group has shifted slightly to around CHF 167, with recent CHF 1 and CHF 17 target reductions from different firms. These moves have led analysts to fine tune assumptions on discount rate, revenue growth, profit margin and future P/E, without changing the overall valuation picture in a major way.Recent updates
Shareholder Returns
| TECN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | -7.2% | -1.5% | 0.8% |
| 1Y | -11.5% | -12.7% | 7.5% |
Return vs Industry: TECN matched the Swiss Life Sciences industry which returned -10.9% over the past year.
Return vs Market: TECN underperformed the Swiss Market which returned 7.1% over the past year.
Price Volatility
| TECN volatility | |
|---|---|
| TECN Average Weekly Movement | 5.9% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.8% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: TECN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: TECN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 3,166 | Monica Manotas | www.tecan.com |
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution.
Tecan Group AG Fundamentals Summary
| TECN fundamental statistics | |
|---|---|
| Market cap | CHF 1.90b |
| Earnings (TTM) | -CHF 110.65m |
| Revenue (TTM) | CHF 882.48m |
Is TECN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TECN income statement (TTM) | |
|---|---|
| Revenue | CHF 882.48m |
| Cost of Revenue | CHF 571.64m |
| Gross Profit | CHF 310.84m |
| Other Expenses | CHF 421.49m |
| Earnings | -CHF 110.65m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 11, 2026
| Earnings per share (EPS) | -8.83 |
| Gross Margin | 35.22% |
| Net Profit Margin | -12.54% |
| Debt/Equity Ratio | 13.1% |
How did TECN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 06:32 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tecan Group AG is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harry Gillis | Berenberg |
| Delphine Le Louet | Bernstein |
| Susannah Ludwig | Bernstein |